Association of the Novel Inflammatory Marker GlycA and Incident Heart Failure and Its Subtypes of Preserved and Reduced Ejection Fraction: The Multi-Ethnic Study of Atherosclerosis

GlycA, a nuclear magnetic resonance composite marker of systemic inflammation, reflects serum concentration and glycosylation state of main acute phase reactants. Prior studies have shown plasma GlycA levels were associated with cardiovascular disease even after adjusting for other inflammatory mark...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation. Heart failure 2020-08, Vol.13 (8), p.e007067-e007067
Hauptverfasser: Jang, Sunyoung, Ogunmoroti, Oluseye, Ndumele, Chiadi E., Zhao, Di, Rao, Vishal N., Fashanu, Oluwaseun E., Tibuakuu, Martin, Otvos, James D., Benson, Eve-Marie, Ouyang, Pamela, Michos, Erin D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e007067
container_issue 8
container_start_page e007067
container_title Circulation. Heart failure
container_volume 13
creator Jang, Sunyoung
Ogunmoroti, Oluseye
Ndumele, Chiadi E.
Zhao, Di
Rao, Vishal N.
Fashanu, Oluwaseun E.
Tibuakuu, Martin
Otvos, James D.
Benson, Eve-Marie
Ouyang, Pamela
Michos, Erin D.
description GlycA, a nuclear magnetic resonance composite marker of systemic inflammation, reflects serum concentration and glycosylation state of main acute phase reactants. Prior studies have shown plasma GlycA levels were associated with cardiovascular disease even after adjusting for other inflammatory markers. However, little is known about the association of GlycA with the heart failure (HF) subtypes: heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction. We examined the association of GlycA with incident HF and its subtypes in a multiethnic cohort. We studied 6507 Multi-Ethnic Study of Atherosclerosis participants aged 45 to 84 without baseline cardiovascular disease or HF who had data on GlycA and incident hospitalized HF. We used multivariable-adjusted Cox hazards models to evaluate the association of GlycA with incident total HF, HFpEF, and heart failure with reduced ejection fraction. Models were adjusted for sociodemographics, cardiovascular disease risk factors, and inflammatory biomarkers. The mean (SD) for age was 62 (10) years and for GlycA was 375 (82) μmol/L; 53% women. Over a median follow-up of 14.0 years, participants in the highest quartile of GlycA, compared with the lowest, experienced increased risk of developing any HF (hazard ratio, 1.48 [95% CI, 1.01-2.18]) in fully adjusted models. However, this increased risk was only seen for HFpEF (2.18 [1.15-4.13]) and not heart failure with reduced ejection fraction [1.06 (0.63-1.79)]. There was no significant interaction by sex, age, or race/ethnicity. GlycA was associated with an increased risk of any HF, and in particular, HFpEF. Future studies should examine mechanisms that might explain differential association of GlycA with HF subtypes, and whether therapeutic lowering of GlycA can prevent HFpEF development. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00005487.
doi_str_mv 10.1161/CIRCHEARTFAILURE.120.007067
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7438279</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2431811701</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3638-eb13ef7c255773bda152fb7c6ef503b7d928842216d682cea51b287399fbf8a33</originalsourceid><addsrcrecordid>eNpdUV1v0zAUjRATG4O_gCzxwks6fySxAxJSVLVrpQ5Q1z1bjnNDs7lxsZ1O_V_8QNx2TIMHX1_pnHvOvTpJ8pHgESEFuRrPl-PZpFquptV8cbecjAjFI4w5Lvir5IKUGUkZLfnrF_158tb7e4wLmuflm-ScUV7QLBcXye_Ke6s7FTrbI9uisAb0ze7AoHnfGrXZqGDdHt0o9wAOXZu9rpDqm4jqroE-oBkoF9BUdWZwcIKCR7dDHfZb8AfJHw48uB00R3QJzaBjP7kHfTSdOnVsPqNV9L4ZTOjSSVj3nUa3YWj2B4kqruWs1-ZQO_8uOWuV8fD-6b9M7qaT1XiWLr5fz8fVItWsYCKFmjBouY5Hc87qRpGctjXXBbQ5ZjVvSipERikpmkJQDSonNRWclWVbt0Ixdpl8Peluh3oDjY73OmXk1nUb5fbSqk7-i_TdWv60O8kzJigvo8CnJwFnfw3gg9x0XoMxqgc7eEkzRgQhHJNI_XKi6niid9A-2xAsD7nL_3OXMXd5yj1Of3i56fPs36AjITsRHq0J4PyDGR7ByTUoE9Yy-jOelVlKMcVYYIzT-LBgfwAP9b8m</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2431811701</pqid></control><display><type>article</type><title>Association of the Novel Inflammatory Marker GlycA and Incident Heart Failure and Its Subtypes of Preserved and Reduced Ejection Fraction: The Multi-Ethnic Study of Atherosclerosis</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Jang, Sunyoung ; Ogunmoroti, Oluseye ; Ndumele, Chiadi E. ; Zhao, Di ; Rao, Vishal N. ; Fashanu, Oluwaseun E. ; Tibuakuu, Martin ; Otvos, James D. ; Benson, Eve-Marie ; Ouyang, Pamela ; Michos, Erin D.</creator><creatorcontrib>Jang, Sunyoung ; Ogunmoroti, Oluseye ; Ndumele, Chiadi E. ; Zhao, Di ; Rao, Vishal N. ; Fashanu, Oluwaseun E. ; Tibuakuu, Martin ; Otvos, James D. ; Benson, Eve-Marie ; Ouyang, Pamela ; Michos, Erin D.</creatorcontrib><description>GlycA, a nuclear magnetic resonance composite marker of systemic inflammation, reflects serum concentration and glycosylation state of main acute phase reactants. Prior studies have shown plasma GlycA levels were associated with cardiovascular disease even after adjusting for other inflammatory markers. However, little is known about the association of GlycA with the heart failure (HF) subtypes: heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction. We examined the association of GlycA with incident HF and its subtypes in a multiethnic cohort. We studied 6507 Multi-Ethnic Study of Atherosclerosis participants aged 45 to 84 without baseline cardiovascular disease or HF who had data on GlycA and incident hospitalized HF. We used multivariable-adjusted Cox hazards models to evaluate the association of GlycA with incident total HF, HFpEF, and heart failure with reduced ejection fraction. Models were adjusted for sociodemographics, cardiovascular disease risk factors, and inflammatory biomarkers. The mean (SD) for age was 62 (10) years and for GlycA was 375 (82) μmol/L; 53% women. Over a median follow-up of 14.0 years, participants in the highest quartile of GlycA, compared with the lowest, experienced increased risk of developing any HF (hazard ratio, 1.48 [95% CI, 1.01-2.18]) in fully adjusted models. However, this increased risk was only seen for HFpEF (2.18 [1.15-4.13]) and not heart failure with reduced ejection fraction [1.06 (0.63-1.79)]. There was no significant interaction by sex, age, or race/ethnicity. GlycA was associated with an increased risk of any HF, and in particular, HFpEF. Future studies should examine mechanisms that might explain differential association of GlycA with HF subtypes, and whether therapeutic lowering of GlycA can prevent HFpEF development. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00005487.</description><identifier>ISSN: 1941-3297</identifier><identifier>ISSN: 1941-3289</identifier><identifier>EISSN: 1941-3297</identifier><identifier>DOI: 10.1161/CIRCHEARTFAILURE.120.007067</identifier><identifier>PMID: 32762458</identifier><language>eng</language><publisher>United States: American Heart Association, Inc</publisher><subject>Acute-Phase Proteins - metabolism ; Aged ; Aged, 80 and over ; Atherosclerosis - blood ; Atherosclerosis - ethnology ; Biomarkers - blood ; Ethnic Groups ; Female ; Glycosylation ; Heart Failure - blood ; Heart Failure - ethnology ; Humans ; Incidence ; Inflammation - blood ; Inflammation - ethnology ; Male ; Middle Aged ; Risk Assessment ; Risk Factors ; Stroke Volume</subject><ispartof>Circulation. Heart failure, 2020-08, Vol.13 (8), p.e007067-e007067</ispartof><rights>American Heart Association, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3638-eb13ef7c255773bda152fb7c6ef503b7d928842216d682cea51b287399fbf8a33</cites><orcidid>0000-0002-5547-5084</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,3687,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32762458$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jang, Sunyoung</creatorcontrib><creatorcontrib>Ogunmoroti, Oluseye</creatorcontrib><creatorcontrib>Ndumele, Chiadi E.</creatorcontrib><creatorcontrib>Zhao, Di</creatorcontrib><creatorcontrib>Rao, Vishal N.</creatorcontrib><creatorcontrib>Fashanu, Oluwaseun E.</creatorcontrib><creatorcontrib>Tibuakuu, Martin</creatorcontrib><creatorcontrib>Otvos, James D.</creatorcontrib><creatorcontrib>Benson, Eve-Marie</creatorcontrib><creatorcontrib>Ouyang, Pamela</creatorcontrib><creatorcontrib>Michos, Erin D.</creatorcontrib><title>Association of the Novel Inflammatory Marker GlycA and Incident Heart Failure and Its Subtypes of Preserved and Reduced Ejection Fraction: The Multi-Ethnic Study of Atherosclerosis</title><title>Circulation. Heart failure</title><addtitle>Circ Heart Fail</addtitle><description>GlycA, a nuclear magnetic resonance composite marker of systemic inflammation, reflects serum concentration and glycosylation state of main acute phase reactants. Prior studies have shown plasma GlycA levels were associated with cardiovascular disease even after adjusting for other inflammatory markers. However, little is known about the association of GlycA with the heart failure (HF) subtypes: heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction. We examined the association of GlycA with incident HF and its subtypes in a multiethnic cohort. We studied 6507 Multi-Ethnic Study of Atherosclerosis participants aged 45 to 84 without baseline cardiovascular disease or HF who had data on GlycA and incident hospitalized HF. We used multivariable-adjusted Cox hazards models to evaluate the association of GlycA with incident total HF, HFpEF, and heart failure with reduced ejection fraction. Models were adjusted for sociodemographics, cardiovascular disease risk factors, and inflammatory biomarkers. The mean (SD) for age was 62 (10) years and for GlycA was 375 (82) μmol/L; 53% women. Over a median follow-up of 14.0 years, participants in the highest quartile of GlycA, compared with the lowest, experienced increased risk of developing any HF (hazard ratio, 1.48 [95% CI, 1.01-2.18]) in fully adjusted models. However, this increased risk was only seen for HFpEF (2.18 [1.15-4.13]) and not heart failure with reduced ejection fraction [1.06 (0.63-1.79)]. There was no significant interaction by sex, age, or race/ethnicity. GlycA was associated with an increased risk of any HF, and in particular, HFpEF. Future studies should examine mechanisms that might explain differential association of GlycA with HF subtypes, and whether therapeutic lowering of GlycA can prevent HFpEF development. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00005487.</description><subject>Acute-Phase Proteins - metabolism</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Atherosclerosis - blood</subject><subject>Atherosclerosis - ethnology</subject><subject>Biomarkers - blood</subject><subject>Ethnic Groups</subject><subject>Female</subject><subject>Glycosylation</subject><subject>Heart Failure - blood</subject><subject>Heart Failure - ethnology</subject><subject>Humans</subject><subject>Incidence</subject><subject>Inflammation - blood</subject><subject>Inflammation - ethnology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Stroke Volume</subject><issn>1941-3297</issn><issn>1941-3289</issn><issn>1941-3297</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUV1v0zAUjRATG4O_gCzxwks6fySxAxJSVLVrpQ5Q1z1bjnNDs7lxsZ1O_V_8QNx2TIMHX1_pnHvOvTpJ8pHgESEFuRrPl-PZpFquptV8cbecjAjFI4w5Lvir5IKUGUkZLfnrF_158tb7e4wLmuflm-ScUV7QLBcXye_Ke6s7FTrbI9uisAb0ze7AoHnfGrXZqGDdHt0o9wAOXZu9rpDqm4jqroE-oBkoF9BUdWZwcIKCR7dDHfZb8AfJHw48uB00R3QJzaBjP7kHfTSdOnVsPqNV9L4ZTOjSSVj3nUa3YWj2B4kqruWs1-ZQO_8uOWuV8fD-6b9M7qaT1XiWLr5fz8fVItWsYCKFmjBouY5Hc87qRpGctjXXBbQ5ZjVvSipERikpmkJQDSonNRWclWVbt0Ixdpl8Peluh3oDjY73OmXk1nUb5fbSqk7-i_TdWv60O8kzJigvo8CnJwFnfw3gg9x0XoMxqgc7eEkzRgQhHJNI_XKi6niid9A-2xAsD7nL_3OXMXd5yj1Of3i56fPs36AjITsRHq0J4PyDGR7ByTUoE9Yy-jOelVlKMcVYYIzT-LBgfwAP9b8m</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Jang, Sunyoung</creator><creator>Ogunmoroti, Oluseye</creator><creator>Ndumele, Chiadi E.</creator><creator>Zhao, Di</creator><creator>Rao, Vishal N.</creator><creator>Fashanu, Oluwaseun E.</creator><creator>Tibuakuu, Martin</creator><creator>Otvos, James D.</creator><creator>Benson, Eve-Marie</creator><creator>Ouyang, Pamela</creator><creator>Michos, Erin D.</creator><general>American Heart Association, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5547-5084</orcidid></search><sort><creationdate>20200801</creationdate><title>Association of the Novel Inflammatory Marker GlycA and Incident Heart Failure and Its Subtypes of Preserved and Reduced Ejection Fraction: The Multi-Ethnic Study of Atherosclerosis</title><author>Jang, Sunyoung ; Ogunmoroti, Oluseye ; Ndumele, Chiadi E. ; Zhao, Di ; Rao, Vishal N. ; Fashanu, Oluwaseun E. ; Tibuakuu, Martin ; Otvos, James D. ; Benson, Eve-Marie ; Ouyang, Pamela ; Michos, Erin D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3638-eb13ef7c255773bda152fb7c6ef503b7d928842216d682cea51b287399fbf8a33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acute-Phase Proteins - metabolism</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Atherosclerosis - blood</topic><topic>Atherosclerosis - ethnology</topic><topic>Biomarkers - blood</topic><topic>Ethnic Groups</topic><topic>Female</topic><topic>Glycosylation</topic><topic>Heart Failure - blood</topic><topic>Heart Failure - ethnology</topic><topic>Humans</topic><topic>Incidence</topic><topic>Inflammation - blood</topic><topic>Inflammation - ethnology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Stroke Volume</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jang, Sunyoung</creatorcontrib><creatorcontrib>Ogunmoroti, Oluseye</creatorcontrib><creatorcontrib>Ndumele, Chiadi E.</creatorcontrib><creatorcontrib>Zhao, Di</creatorcontrib><creatorcontrib>Rao, Vishal N.</creatorcontrib><creatorcontrib>Fashanu, Oluwaseun E.</creatorcontrib><creatorcontrib>Tibuakuu, Martin</creatorcontrib><creatorcontrib>Otvos, James D.</creatorcontrib><creatorcontrib>Benson, Eve-Marie</creatorcontrib><creatorcontrib>Ouyang, Pamela</creatorcontrib><creatorcontrib>Michos, Erin D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Circulation. Heart failure</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jang, Sunyoung</au><au>Ogunmoroti, Oluseye</au><au>Ndumele, Chiadi E.</au><au>Zhao, Di</au><au>Rao, Vishal N.</au><au>Fashanu, Oluwaseun E.</au><au>Tibuakuu, Martin</au><au>Otvos, James D.</au><au>Benson, Eve-Marie</au><au>Ouyang, Pamela</au><au>Michos, Erin D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of the Novel Inflammatory Marker GlycA and Incident Heart Failure and Its Subtypes of Preserved and Reduced Ejection Fraction: The Multi-Ethnic Study of Atherosclerosis</atitle><jtitle>Circulation. Heart failure</jtitle><addtitle>Circ Heart Fail</addtitle><date>2020-08-01</date><risdate>2020</risdate><volume>13</volume><issue>8</issue><spage>e007067</spage><epage>e007067</epage><pages>e007067-e007067</pages><issn>1941-3297</issn><issn>1941-3289</issn><eissn>1941-3297</eissn><abstract>GlycA, a nuclear magnetic resonance composite marker of systemic inflammation, reflects serum concentration and glycosylation state of main acute phase reactants. Prior studies have shown plasma GlycA levels were associated with cardiovascular disease even after adjusting for other inflammatory markers. However, little is known about the association of GlycA with the heart failure (HF) subtypes: heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction. We examined the association of GlycA with incident HF and its subtypes in a multiethnic cohort. We studied 6507 Multi-Ethnic Study of Atherosclerosis participants aged 45 to 84 without baseline cardiovascular disease or HF who had data on GlycA and incident hospitalized HF. We used multivariable-adjusted Cox hazards models to evaluate the association of GlycA with incident total HF, HFpEF, and heart failure with reduced ejection fraction. Models were adjusted for sociodemographics, cardiovascular disease risk factors, and inflammatory biomarkers. The mean (SD) for age was 62 (10) years and for GlycA was 375 (82) μmol/L; 53% women. Over a median follow-up of 14.0 years, participants in the highest quartile of GlycA, compared with the lowest, experienced increased risk of developing any HF (hazard ratio, 1.48 [95% CI, 1.01-2.18]) in fully adjusted models. However, this increased risk was only seen for HFpEF (2.18 [1.15-4.13]) and not heart failure with reduced ejection fraction [1.06 (0.63-1.79)]. There was no significant interaction by sex, age, or race/ethnicity. GlycA was associated with an increased risk of any HF, and in particular, HFpEF. Future studies should examine mechanisms that might explain differential association of GlycA with HF subtypes, and whether therapeutic lowering of GlycA can prevent HFpEF development. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00005487.</abstract><cop>United States</cop><pub>American Heart Association, Inc</pub><pmid>32762458</pmid><doi>10.1161/CIRCHEARTFAILURE.120.007067</doi><orcidid>https://orcid.org/0000-0002-5547-5084</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1941-3297
ispartof Circulation. Heart failure, 2020-08, Vol.13 (8), p.e007067-e007067
issn 1941-3297
1941-3289
1941-3297
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7438279
source MEDLINE; American Heart Association Journals; EZB-FREE-00999 freely available EZB journals
subjects Acute-Phase Proteins - metabolism
Aged
Aged, 80 and over
Atherosclerosis - blood
Atherosclerosis - ethnology
Biomarkers - blood
Ethnic Groups
Female
Glycosylation
Heart Failure - blood
Heart Failure - ethnology
Humans
Incidence
Inflammation - blood
Inflammation - ethnology
Male
Middle Aged
Risk Assessment
Risk Factors
Stroke Volume
title Association of the Novel Inflammatory Marker GlycA and Incident Heart Failure and Its Subtypes of Preserved and Reduced Ejection Fraction: The Multi-Ethnic Study of Atherosclerosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T05%3A37%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20the%20Novel%20Inflammatory%20Marker%20GlycA%20and%20Incident%20Heart%20Failure%20and%20Its%20Subtypes%20of%20Preserved%20and%20Reduced%20Ejection%20Fraction:%20The%20Multi-Ethnic%20Study%20of%20Atherosclerosis&rft.jtitle=Circulation.%20Heart%20failure&rft.au=Jang,%20Sunyoung&rft.date=2020-08-01&rft.volume=13&rft.issue=8&rft.spage=e007067&rft.epage=e007067&rft.pages=e007067-e007067&rft.issn=1941-3297&rft.eissn=1941-3297&rft_id=info:doi/10.1161/CIRCHEARTFAILURE.120.007067&rft_dat=%3Cproquest_pubme%3E2431811701%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2431811701&rft_id=info:pmid/32762458&rfr_iscdi=true